Skip to main content

 Scientific publications

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Authors : De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, van de Vijver KK, Amant F, Vandecasteele K, Denys HG
Year : 2023
Journal : Cancer Immunol Immunother
Volume : 72
Pages : 475-491

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

Authors : Geukens T, Brandão M, Laenen A, Collignon J, Van Marcke C, Louviaux I, Demey W, Van Wambeke S, Schrijvers D, Lecomte S, Mebis J, Rutten A, Fontaine C, Lybaert W, Aspeslagh S, Goeminne JC, Van den Bulck H, Seront E, De Backer L, De Roock W, Ignatiadis M, Prenen H, Van Beckhoven D, Heijlen M, Verheezen J, Rottey S, Punie K, de Azambuja E
Year : 2022
Journal : ESMO Open
Volume : 7
Pages : 100610

Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.

Authors : Orte Cano C, Van Meerhaeghe T, Tannous J, Lienard D, Van Gestel D, Cuylits N, Luce S, Carlot S, Le Moine A, Aspeslagh S, Del Marmol V
Year : 2022
Journal : J Eur Acad Dermatol Venereol
Volume : 36 Suppl 1
Pages : 53-58

Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.

Authors : Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S
Year : 2021
Journal : Acta Clin Belg
Volume : 76
Pages : 144-148

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors : Wang X, Suppa M, Bruderer P, Sirtaine N, Aspeslagh S, Kerger J
Year : 2021
Journal : Case Rep Oncol
Volume : 14
Pages : 861-867

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

Authors : de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, Collignon J, Lybaert W, Verheezen J, Rutten A, Vuylsteke P, Goeminne JC, Demey W, Van Beckhoven D, Deblonde J, Rottey S, Geukens T, Punie K
Year : 2020
Journal : ESMO Open
Volume : 5

Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids

Authors : Sadek M, Loizidou A, Drowart A, Van den Wijngaert S, Gomez Galdon M, Aspeslagh S
Year : 2020
Journal : JIPO
Volume : 3(1)
Pages : 27-30

Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

Authors : De Bruyn P, Van Gestel D, Ost P, Kruse V, Brochez L, Van Vlierberghe H, Devresse A, Del Marmol V, Le Moine A, Aspeslagh S
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 54-64

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Authors : Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 420-423

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Authors : Tuyaerts S, Van Nuffel AMT, Naert E, van Dam PA, Vuylsteke P, De Caluwe A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 506

Cancer immunotherapy-associated hypophysitis.

Authors : Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L
Year : 2018
Journal : Semin Oncol
Volume : 45
Pages : 181-186

Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.

Authors : De Meulenaere A, Vermassen T, Creytens D, Aspeslagh S, Deron P, Duprez F, Rottey S, Van Dorpe JA, Ferdinande L
Year : 2018
Journal : Histopathology
Volume : 73
Pages : 500-509

Immuno-oncology-101: overview of major concepts and translational perspectives.

Authors : Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 1-11

Epigenetic modifiers as new immunomodulatory therapies in solid tumours.

Authors : Aspeslagh S, Morel D, Soria JC, Postel-Vinay S
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 812-824

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Authors : Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O
Year : 2018
Journal : Eur J Cancer
Volume : 91
Pages : 21-29

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Authors : Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S
Year : 2017
Journal : Eur J Cancer
Volume : 85
Pages : 67-77

Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.

Authors : De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, Rottey S
Year : 2017
Journal : Oral Oncol
Volume : 70
Pages : 34-42

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Authors : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A
Year : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 691

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Authors : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27
Pages : 1021-7